HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

[Anti-ischemic effect of 8 mg molsidomin in retard form].

Abstract
Studies of the efficacy of molsidomine, previously performed on our service, demonstrated that a clear antianginal effect in the longterm treatment of angina pectoris could only be achieved with a regimen of the standard 2 mg dose when given six times daily. Consequently, since a mode of administration with a longer duration of action was implicitly desirable, the present study, carried out in eleven patients with coronary artery disease and stable, exertional angina pectoris, was undertaken to assess the antiischemic effects of 8 mg molsidomine in sustained-release form as compared with the standard 2 mg formulation according to a double-blind, randomized, crossover, placebo-controlled protocol. Additionally, plasma concentrations of molsidomine were determined to elucidate the bioavailability as well as possible correlations between plasma concentrations and antiischemic effect. As compared with placebo, after administration of 8 mg molsidomine sustained-release there were reduction in the ST-segment depression at one, three, five and eight hours of 74% (p less than 0.001), 61% (p less than 0.001), 44% (p less than 0.025), and 31% (p less than 0.01), respectively; after 2 mg molsidomine, 74% (p less than 0.001), 37% (p less than 0.025), 7% (ns) and 6% (ns), respectively. Analysis of the response of the ST-segment in the individual patients showed an unequivocal antiischemic effect with a reduction in ST-segment depression of at least 1 mm after 8 mg molsidomine sustained-release at the specified points in time in ten, five, six and four patients, respectively, and after 2 mg molsidomine in nine, five, one and no patients, respectively.(ABSTRACT TRUNCATED AT 250 WORDS)
AuthorsR Blasini, U Brügmann, W Rudolph
JournalHerz (Herz) Vol. 9 Issue 6 Pg. 346-52 (Dec 1984) ISSN: 0340-9937 [Print] Germany
Vernacular TitleAntiischämische Wirkung von 8 mg Molsidomin in Retardform.
PMID6392050 (Publication Type: Clinical Trial, English Abstract, Journal Article, Randomized Controlled Trial)
Chemical References
  • Delayed-Action Preparations
  • Oxadiazoles
  • Sydnones
  • Vasodilator Agents
  • Molsidomine
Topics
  • Angina Pectoris (drug therapy)
  • Blood Pressure (drug effects)
  • Clinical Trials as Topic
  • Coronary Circulation (drug effects)
  • Coronary Disease (drug therapy)
  • Delayed-Action Preparations
  • Dose-Response Relationship, Drug
  • Double-Blind Method
  • Electrocardiography
  • Heart Rate (drug effects)
  • Humans
  • Molsidomine
  • Oxadiazoles (therapeutic use)
  • Sydnones (blood, therapeutic use)
  • Vasodilator Agents (blood, therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: